Late in January, news regarding disruptions in vaccine production spread across markets and media. Should it be the case that vaccination plans are pushed back, projected economic scenarios could change radically, with the subsequent impact on company valuations and credit balance. On the other hand, we also learned that two more vaccines, developed by Novavax and Janssen, have rendered positive efficacy results. Moreover, current vaccines are also proving effective in fighting emerging coronavirus mutations.